Oral bacitracin: A consideration for suppression of intestinal vancomycin-resistant enterococci (VRE) and for VRE bacteremia from an apparent gastrointestinal tract source

Tran, T. T., Palmer, H. R., Weimar, M. R., Arias, C. A., Cook, G. M., & Murray, B. E. (2015, June 1). Oral bacitracin: A consideration for suppression of intestinal vancomycin-resistant enterococci (VRE) and for VRE bacteremia from an apparent gastrointestinal tract source. Clinical Infectious Diseases. Oxford University Press. https://doi.org/10.1093/cid/civ130